An international consortium of researchers on a multi-centre study on congenital stationary night blindness (CSNB), led by Oregon Health and Science University Casey Eye Institute,… Read More »An international multi-centre study on congenital stationary night blindness (CSNB) report several genetic variants on myopia.
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT), based in Emeryville, California, have announced interim 24-week data from their “PRISM” (WET AMD) and “SPECTRA” (DME) phase I/II… Read More »Positive results from 4DMT announce an improvement on BCVA for a dual-transgene treatment for wet AMD and DME.
Dear EURETINA Members, A very warm welcome to the August 8th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »August 8th, 2024 “EURETINA-Brief”© Issue No. 297
In a recent study published in the prestigious journal Nature Communications (2024 Jul 21;15[1]:6150), researchers have reported that an upstream regulator, “AKT2” (a member of… Read More »Researchers identify that lysosomal biogenesis and mitochondrial signalling may suggest new therapeutic targets for dry-AMD.
Researchers at Janssen Pharmaceuticals N.V. and the ERN-EYE Network at the Center for Retinitis Pigmentosa of Veneto Region, Camposampiero Hospital, Padua, Italy, have reported results… Read More »Results from a cross sectional study of XLRP patients suggest that several healthcare systems require early diagnosis and effective management of patients.
Kiora Pharmaceuticals (NASDAQ: KPRX) have announced the receipt of Orphan Medicinal Product Designation from the European Medicines Agency (EMA) for the treatment of IRDs, including… Read More »Kioro Pharmaceuticals (NASDAQ: KPRX) has announced Orphan Medicinal Product Designation for KIO-310, for the treatment of non-syndromic rod-dominant retinal dystrophies.
Dear EURETINA Members, A very warm welcome to the July 24th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »July 24th, 2024 “EURETINA-Brief”© Issue No. 296
Researchers at the School of Pharmacy, University of Eastern Finland, and the Gavin Herbert Eye Institute-Center for Translational Vision Research, Department of Ophthalmology, University of… Read More »Re-purposed drugs for retinitis pigmentosa may address mutation-independent approach for retinal degenerations.
Researchers at UCL Institute of Ophthalmology, University College London, and Moorfields Eye Hospital, have reported a detailed natural history, retinal imaging dataset and clinical features… Read More »A first in-depth retrospective longitudinal study of Usher syndrome on USH1D, providing key natural history, image data and clinical features.
A private biotech company, Beacon Therapeutics, based in London, UK (and Florida and Cambridge, USA), has received an investment of $170M from several funding partners,… Read More »Beacon Therapeutics has announced an investment of $170M for the development of ophthalmic gene therapies.
